Frovatriptan use in migraineurs with or at high risk of coronary artery disease.

Author: ElkindArthur H, KeywoodCharlotte, NilaAlice, SatinLawrence Z

Paper Details 
Original Abstract of the Article :
OBJECTIVE: To investigate the cardiovascular effects of frovatriptan 2.5 mg during a migraine attack in patients with, or at high risk of, coronary artery disease. BACKGROUND: Rare occurrences of myocardial ischemia and coronary and peripheral vasospasm associated with the use of sumatriptan have t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/15147247

データ提供:米国国立医学図書館(NLM)

Frovatriptan for Migraines: A Safe Haven in the Desert of Pain

Migraines, a relentless and debilitating condition, can leave individuals feeling lost in a desert of pain. This study explores the cardiovascular effects of frovatriptan, a triptan medication used to treat migraines, in patients with or at high risk of coronary artery disease. The research involved a randomized, double-blind, placebo-controlled study to evaluate the safety of frovatriptan in this patient population. The findings provide valuable insights into the cardiovascular safety of frovatriptan, offering a potential treatment option for individuals with migraines and pre-existing cardiovascular conditions.

Navigating the Migraine Treatment Landscape

The study found that frovatriptan 2.5 mg was well-tolerated in patients with or at high risk of coronary artery disease and was not associated with an increase in cardiovascular monitoring abnormalities. This finding is significant as it suggests that frovatriptan may be a safe and effective treatment option for individuals with migraines and pre-existing cardiovascular conditions. However, it is crucial to approach migraine treatment with caution and to consult with a healthcare professional to determine the most appropriate treatment plan.

Navigating the Migraine Treatment Landscape

The study found that frovatriptan 2.5 mg was well-tolerated in patients with or at high risk of coronary artery disease and was not associated with an increase in cardiovascular monitoring abnormalities. This finding is significant as it suggests that frovatriptan may be a safe and effective treatment option for individuals with migraines and pre-existing cardiovascular conditions. However, it is crucial to approach migraine treatment with caution and to consult with a healthcare professional to determine the most appropriate treatment plan.

Dr. Camel's Conclusion

Navigating the desert of migraine pain can be an arduous journey, with many individuals seeking a reliable source of relief. This study offers a glimmer of hope, suggesting that frovatriptan may be a safe and effective haven for individuals with migraines and pre-existing cardiovascular conditions. While further research is always needed to refine our understanding of the complex interplay of migraine and cardiovascular health, this study provides valuable insights into the potential benefits of frovatriptan for this patient population.

Date :
  1. Date Completed 2004-08-12
  2. Date Revised 2012-11-15
Further Info :

Pubmed ID

15147247

DOI: Digital Object Identifier

HED04071

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.